{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:47:09Z","timestamp":1791589629372,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T00:00:00Z","timestamp":1439251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T00:00:00Z","timestamp":1439251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1038\/pcan.2015.39","type":"journal-article","created":{"date-parts":[[2015,8,11]],"date-time":"2015-08-11T06:21:33Z","timestamp":1439274093000},"page":"325-332","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":165,"title":["Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance"],"prefix":"10.1038","volume":"18","author":[{"given":"A M","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T R","family":"Nirschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C J","family":"Nirschl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B J","family":"Francica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C M","family":"Kochel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"van Bokhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A K","family":"Meeker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"Lucia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R A","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"DeMarzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C G","family":"Drake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,11]]},"reference":[{"key":"BFpcan201539_CR1","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793\u2013800.","journal-title":"Nat Med"},{"key":"BFpcan201539_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2326","volume":"8","author":"W Zou","year":"2008","unstructured":"Zou W, Chen L . Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008; 8: 467\u2013477.","journal-title":"Nat Rev Immunol"},{"key":"BFpcan201539_CR3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrclinonc.2013.208","volume":"11","author":"CG Drake","year":"2014","unstructured":"Drake CG, Lipson EJ, Brahmer JR . Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014; 11: 24\u201337.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFpcan201539_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.coi.2011.12.009","volume":"24","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Drake CG, Pardoll DM . Targeting the PD-1\/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012; 24: 207\u2013212.","journal-title":"Curr Opin Immunol"},{"key":"BFpcan201539_CR5","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252\u2013264.","journal-title":"Nat Rev Cancer"},{"issue":"Suppl","key":"BFpcan201539_CR6","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/jco.2013.31.15_suppl.3002","volume":"31","author":"SL Topalian","year":"2013","unstructured":"Topalian SL, Sznol M, Brahmer JR, McDermott DF, Smith DC, Gettinger SN et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with advanced solid tumors: survival and long-term safety in a phase I trial [abstract]. J Clin Oncol 2013; 31 (Suppl): 3002.","journal-title":"J Clin Oncol"},{"key":"BFpcan201539_CR7","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167\u20133175.","journal-title":"J Clin Oncol"},{"key":"BFpcan201539_CR8","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4: 127ra37.","journal-title":"Sci Transl Med"},{"key":"BFpcan201539_CR9","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443\u20132454.","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"BFpcan201539_CR10","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/jco.2013.31.15_suppl.3016","volume":"31","author":"JF Grosso","year":"2013","unstructured":"Grosso JF, Horak CE, Inzunza D, Cardona DM, Simon JS, Gupta AK et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538) [abstract]. J Clin Oncol 2013; 31 (Suppl): 3016.","journal-title":"J Clin Oncol"},{"key":"BFpcan201539_CR11","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, Chen L . B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365\u20131369.","journal-title":"Nat Med"},{"key":"BFpcan201539_CR12","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1084\/jem.20112275","volume":"209","author":"D Pardoll","year":"2012","unstructured":"Pardoll D, Drake C . Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med 2012; 209: 201\u2013209.","journal-title":"J Exp Med"},{"key":"BFpcan201539_CR13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/nm1517","volume":"13","author":"AT Parsa","year":"2007","unstructured":"Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med 2007; 13: 84\u201388.","journal-title":"Nat Med"},{"key":"BFpcan201539_CR14","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/onc.2008.384","volume":"28","author":"C Crane","year":"2009","unstructured":"Crane C, Panner A, Murray J, Wilson S, Xu H, Chen L et al. PI (3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. Oncogene 2009; 28: 306\u2013312.","journal-title":"Oncogene"},{"key":"BFpcan201539_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/path.2559","volume":"218","author":"K Sircar","year":"2009","unstructured":"Sircar K, Yoshimoto M, Monzon FA, Koumakpayi IH, Katz RL, Khanna A et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009; 218: 505\u2013513.","journal-title":"J Pathol"},{"key":"BFpcan201539_CR16","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1158\/1078-0432.CCR-11-1244","volume":"17","author":"TL Lotan","year":"2011","unstructured":"Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 2011; 17: 6563\u20136573.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201539_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/modpathol.2012.162","volume":"26","author":"M Yoshimoto","year":"2013","unstructured":"Yoshimoto M, Ding K, Sweet JM, Ludkovski O, Trottier G, Song KS et al. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol 2013; 26: 435\u2013447.","journal-title":"Mod Pathol"},{"key":"BFpcan201539_CR18","doi-asserted-by":"publisher","first-page":"6063","DOI":"10.1002\/cncr.27689","volume":"118","author":"ES Antonarakis","year":"2012","unstructured":"Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer 2012; 118: 6063\u20136071.","journal-title":"Cancer"},{"key":"BFpcan201539_CR19","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1093\/jnci\/85.5.394","volume":"85","author":"TG Pretlow","year":"1993","unstructured":"Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI et al. Xenografts of primary human prostatic carcinoma. J Natl Cancer Inst 1993; 85: 394\u2013398.","journal-title":"J Natl Cancer Inst"},{"key":"BFpcan201539_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/pros.20053","volume":"60","author":"S Koochekpour","year":"2004","unstructured":"Koochekpour S, Maresh GA, Katner A, Parker\u2010Johnson K, Lee T, Hebert FE et al. Establishment and characterization of a primary androgen\u2010responsive African\u2010American prostate cancer cell line, E006AA. Prostate 2004; 60: 141\u2013152.","journal-title":"Prostate"},{"key":"BFpcan201539_CR21","doi-asserted-by":"crossref","unstructured":"Russell PJ, Kingsley EA . Human prostate cancer cell lines. In: Walker JM (ed), Prostate Cancer Methods and Protocols, Vol. 81. Springer: Berlin, Germany, 2003, pp 21\u201339.","DOI":"10.1385\/1592593720"},{"key":"BFpcan201539_CR22","first-page":"163","volume":"15","author":"S Korenchuk","year":"2001","unstructured":"Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R et al. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001; 15: 163\u2013168.","journal-title":"In Vivo"},{"key":"BFpcan201539_CR23","doi-asserted-by":"publisher","first-page":"6822","DOI":"10.4049\/jimmunol.1003682","volume":"186","author":"ST Haile","year":"2011","unstructured":"Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK et al. Tumor cell programmed death ligand 1-mediated T-cell suppression is overcome by coexpression of CD80. J Immunol 2011; 186: 6822\u20136829.","journal-title":"J Immunol"},{"key":"BFpcan201539_CR24","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1038\/onc.2011.144","volume":"30","author":"Y Wang","year":"2011","unstructured":"Wang Y, Romigh T, He X, Tan M, Orloff M, Silverman R et al. Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene 2011; 30: 4327\u20134338.","journal-title":"Oncogene"},{"key":"BFpcan201539_CR25","doi-asserted-by":"crossref","unstructured":"Goldberg MV, Drake CG . LAG-3 in cancer immunotherapy. In: Dranoff G (ed), Cancer Immunology and Immunotherapy, Vol. 344. Springer: Berlin, Gemany, 2011, pp 269\u2013278.","DOI":"10.1007\/82_2010_114"},{"key":"BFpcan201539_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1126\/science.8016643","volume":"265","author":"V Steimle","year":"1994","unstructured":"Steimle V, Siegrist CA, Mottet A, Lisowska-Grospierre B, Mach B . Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science 1994; 265: 106\u2013109.","journal-title":"Science"},{"key":"BFpcan201539_CR27","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.4049\/jimmunol.1000496","volume":"185","author":"PY Lin","year":"2010","unstructured":"Lin PY, Sun L, Thibodeaux SR, Ludwig SM, Vadlamudi RK, Hurez VJ et al. B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol 2010; 185: 2747\u20132753.","journal-title":"J Immunol"},{"key":"BFpcan201539_CR28","doi-asserted-by":"publisher","first-page":"14980","DOI":"10.1074\/jbc.M109.085696","volume":"285","author":"X Jiang","year":"2010","unstructured":"Jiang X, Chen S, Asara JM, Balk SP . Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits. J Biol Chem 2010; 285: 14980\u201314989.","journal-title":"J Biol Chem"},{"key":"BFpcan201539_CR29","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1016\/S0002-9440(10)65517-4","volume":"155","author":"AM De Marzo","year":"1999","unstructured":"De Marzo AM, Marchi VL, Epstein JI, Nelson WG . Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985\u20131992.","journal-title":"Am J Pathol"},{"key":"BFpcan201539_CR30","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria J, Kowanetz M, Fine GD, Hamid O, Gordon MS et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563\u2013567.","journal-title":"Nature"},{"key":"BFpcan201539_CR31","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/eji.200425531","volume":"35","author":"E Degl'Innocenti","year":"2005","unstructured":"Degl'Innocenti E, Grioni M, Boni A, Camporeale A, Bertilaccio MT, Freschi M et al. Peripheral T-cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur J Immunol 2005; 35: 66\u201375.","journal-title":"Eur J Immunol"},{"key":"BFpcan201539_CR32","doi-asserted-by":"publisher","first-page":"13003","DOI":"10.1073\/pnas.0805599105","volume":"105","author":"A Bai","year":"2008","unstructured":"Bai A, Higham E, Eisen HN, Wittrup KD, Chen J . Rapid tolerization of virus-activated tumor-specific CD8+ T-cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci USA 2008; 105: 13003\u201313008.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFpcan201539_CR33","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1158\/1078-0432.CCR-13-2797","volume":"20","author":"M Atefi","year":"2014","unstructured":"Atefi M, Avramis E, Lassen A, Wong DJ, Robert L, Foulad D et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res 2014; 20: 3446\u20133457.","journal-title":"Clin Cancer Res"},{"key":"BFpcan201539_CR34","doi-asserted-by":"publisher","first-page":"14565","DOI":"10.1073\/pnas.251140998","volume":"98","author":"M Mercader","year":"2001","unstructured":"Mercader M, Bodner BK, Moser MT, Kwon PS, Park ES, Manecke RG et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001; 98: 14565\u201314570.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFpcan201539_CR35","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jim.2009.06.004","volume":"348","author":"PO Gannon","year":"2009","unstructured":"Gannon PO, Poisson AO, Delvoye N, Lapointe R, Mes-Masson A, Saad F . Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009; 348: 9\u201317.","journal-title":"J Immunol Methods"},{"key":"BFpcan201539_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.2741\/2441","volume":"12","author":"JB Aragon-Ching","year":"2007","unstructured":"Aragon-Ching JB, Williams KM, Gulley JL . Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007; 12: 71.","journal-title":"Front Biosci"},{"key":"BFpcan201539_CR37","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/nri2817","volume":"10","author":"CG Drake","year":"2010","unstructured":"Drake CG . Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010; 10: 580\u2013593.","journal-title":"Nat Rev Immunol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan201539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201539","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201539.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T17:20:53Z","timestamp":1648660853000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,11]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["BFpcan201539"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2015.39","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,11]]},"assertion":[{"value":"29 April 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2015","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CGD has consulted for Amplimmune, Bristol Myers Squibb (BMS), Merck and Roche-Genentech, all of whom have either anti-PD-1 or anti-PD-L1 reagents in various stages of clinical development. In addition, Drs Anders and Drake have received sponsored research funding from BMS. The first author Dr Martin has no conflict of interest to declare. All the other authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}